| Symbol
| PPM1D
| contributors: mct/pgu - updated : 09-05-2017
|
| HGNC name
| protein phosphatase 1D magnesium-dependent, delta isoform
|
| HGNC id
| 9277
|
| corresponding disease(s)
|
IDDGIP
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| amplification
|
|
| |
in breast cancer (in progression) | | tumoral
|
|
| --over
|
| |
in several types of cancers | | tumoral
|
|
| --over
|
|
in cancer epithelial cells has significant value for tumor progression and the clinical prognosis of patients with primary lung adenocarcinoma  | | tumoral
| somatic mutation
|
|
| gain of function
| |
in breast and ovarian cancer | | constitutional
|
|
| --low
|
| |
plays an important role in Mn-induced neuronal death in the brain striatum via the modulation of TP53 signaling | |
Variant & Polymorphism
| 
| |
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | reproductive | breast | |
| PPM1D inhibitors should be viable anti-cancer agents | | cancer | brain | glioma/neuroblstoma | |
| PPM1D inhibition represents a novel therapeutic approach to neuroblastoma that could be integrated with current chemotherapeutic approaches |
| | | |
|
| Wip1-/- mice display immunodeficiency, abnormal lymphoid histopathology in thymus and spleen, defects in B- and T-cell differentiation, as well as susceptibility to viral infection | |
Wip1-deficient mice exhibit a significant reduction of B-cell numbers in the bone marrow, peripheral blood, and spleen |